

Strides Arcolab receives USFDA approval for its Italian facility

19 September 2013 | News | By BioSpectrum Bureau

Strides Arcolab receives USFDA approval for its Italian facility



This state-of-the-art, EU and TGA (Therapeutic Goods Administration, Australia) approved facility located in Milan, Italy, manufactures liquids, semi-solids, ointments and creams.

The company is expecting its first approval of a niche semi-solid product by first quarter in 2014.

Commenting on the event, Manish Gupta, CEO - Pharma said, "This approval provides further impetus to our pharma business and marks our foray into the attractive but complex semi-solid market in US. Our first product, which is expected to be commercialized by first quarter in 2014, has undergone extensive clinical trials. The product will be marketed by one of the top 10 generic companies in the US market".

Strides is currently developing a portfolio of liquids and semi-solids products for the US and EU markets, and currently has over 12 products at various stages of development and approvals. Strides already sells semi-solids in the UK market.